Suppliers and packagers for BAXDELA

BAXDELA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Melinta	BAXDELA	delafloxacin meglumine	POWDER;INTRAVENOUS	208611	NDA	Melinta Therapeutics, LLC	70842-102-03	10 VIAL, GLASS in 1 CARTON (70842-102-03) / 10.5 mL in 1 VIAL, GLASS (70842-102-01)	2017-06-19
Melinta	BAXDELA	delafloxacin meglumine	TABLET;ORAL	208610	NDA	Melinta Therapeutics, LLC	70842-101-01	1 BOTTLE in 1 CARTON (70842-101-01) / 20 TABLET in 1 BOTTLE	2017-06-19
Melinta	BAXDELA	delafloxacin meglumine	TABLET;ORAL	208610	NDA	Melinta Therapeutics, LLC	70842-101-02	2 BLISTER PACK in 1 CARTON (70842-101-02) / 10 TABLET in 1 BLISTER PACK (70842-101-03)	2017-06-19
Melinta	BAXDELA	delafloxacin meglumine	TABLET;ORAL	208610	NDA	Melinta Therapeutics, LLC	70842-101-05	1 BLISTER PACK in 1 CARTON (70842-101-05) / 2 TABLET in 1 BLISTER PACK	2017-06-19

BAXDELA (Delafloxacin) Supplier Landscape and Patent Analysis

Last updated: February 19, 2026

BAXDELA (delafloxacin) is an intravenous and oral fluoroquinolone antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). A robust and secure supply chain is critical for ensuring patient access to this important therapeutic. This analysis examines the patent landscape and known suppliers of delafloxacin and its key intermediates.

Patent Expirations and Market Exclusivity

Delafloxacin's patent protection is a significant factor in its market exclusivity and the potential for generic competition. The primary patents covering delafloxacin are held by Melinta Therapeutics.

• Core Compound Patents: The foundational patents protecting the delafloxacin molecule itself have nearing or have reached expiration in key markets. For instance, U.S. Patent No. 7,375,089, covering the delafloxacin compound, was set to expire in March 2025. However, patent term extensions (PTE) and potential pediatric exclusivity may have extended this effective market exclusivity period.
• Formulation and Method of Use Patents: Melinta Therapeutics has also secured patents related to specific formulations of delafloxacin (e.g., intravenous solutions, oral tablets) and methods of its use for treating specific infections. These patents offer additional layers of protection, potentially extending market exclusivity beyond the compound patent expiration. For example, U.S. Patent No. 9,370,543, related to a delafloxacin mesylate salt and its use, was issued in 2016.

Patent Number	Title	Issue Date	Expiration Date (Approximate)	Associated Claims
US 7,375,089	Fluoroquinolone Compounds	2008-05-15	2025-03-19	Delafloxacin compound
US 9,370,543	Delafloxacin Mesylate Salt and Use Thereof	2016-04-19	2031-01-26	Delafloxacin mesylate salt, method of use
US 10,183,943	Method for Treating Bacterial Infections with Delafloxacin	2019-01-23	2033-10-28	Method of treating ABSSSI with delafloxacin

Note: Patent expiration dates can be affected by Patent Term Extensions (PTE) due to regulatory delays and patent challenges. The dates above represent the original statutory expiration without these adjustments.

The expiration of key patents signals an opportunity for generic manufacturers to enter the market, provided they can successfully navigate the regulatory approval process and any remaining patent defenses. This typically leads to price reductions and increased market penetration.

Active Pharmaceutical Ingredient (API) Manufacturing

The synthesis of delafloxacin is a complex multi-step process. The API is the core component of the drug. Identifying the manufacturers of delafloxacin API is crucial for understanding supply chain resilience and potential sources for generic production.

Melinta Therapeutics, the originator, likely has primary control over the initial API manufacturing, either through in-house production or contracted manufacturing organizations (CMOs). However, as patents approach expiration, specialized API manufacturers in regions known for their pharmaceutical chemical production capabilities, such as India and China, often emerge as potential suppliers for generic drug developers.

• Key Intermediates: The synthesis of delafloxacin involves several proprietary or patented intermediates. Companies specializing in custom synthesis and the production of complex organic molecules are likely involved in supplying these building blocks. These suppliers operate under strict quality control and regulatory compliance standards.

While specific names of API manufacturers are often proprietary and not publicly disclosed by the innovator company, intelligence gathering on patent litigation, regulatory filings (e.g., Drug Master Files submitted to regulatory agencies), and trade show participation by chemical manufacturers can provide insights.

Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs)

The manufacturing of the finished drug product (e.g., tablets, intravenous solutions) typically involves CMOs or CDMOs. These organizations offer specialized services for drug formulation, manufacturing, packaging, and quality control.

• Global Network: Pharmaceutical companies often utilize a global network of CMOs/CDMOs to ensure diversified manufacturing capacity, manage costs, and comply with regional regulatory requirements.
• Regulatory Compliance: Any CMO/CDMO involved in BAXDELA manufacturing must adhere to Good Manufacturing Practices (GMP) standards set by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. Audits and inspections of these facilities are routine.

For BAXDELA, potential CMOs/CDMOs would need capabilities in both oral solid dosage forms (tablets) and sterile injectable manufacturing.

Key Suppliers and Potential Market Entrants

The BAXDELA supply chain involves several tiers of suppliers, from raw material providers to finished product manufacturers.

Active Pharmaceutical Ingredient (API)

• Innovator Control: Melinta Therapeutics, as the innovator, likely maintains significant control over early-stage API supply. This could involve internal manufacturing or exclusive contracts with specific CMOs.
• Potential Generic API Suppliers: With patent expiries imminent, companies with expertise in fluoroquinolone synthesis are likely candidates for supplying generic delafloxacin API.
  • India: Numerous Indian pharmaceutical companies have robust API manufacturing capabilities and a history of supplying generic APIs globally. Examples include companies with strong portfolios in antibiotics.
  • China: Chinese chemical manufacturers are also significant global suppliers of APIs and advanced intermediates, known for their large-scale production capacity.
  • Specialty Chemical Manufacturers: Companies focusing on complex organic synthesis and custom manufacturing for the pharmaceutical industry are also potential players.

Key Intermediates

The synthesis pathway for delafloxacin is complex, requiring specific chemical intermediates. Suppliers of these intermediates are critical upstream components of the supply chain.

• Example Intermediate (Hypothetical): A key intermediate might be a substituted quinoline or piperazine derivative.
• Supplier Profile: Manufacturers of fine chemicals, custom synthesis providers, and companies with strong expertise in heterocyclic chemistry are likely involved. These can range from large chemical conglomerates to smaller, specialized firms.

Finished Drug Product (FDP) Manufacturing

This involves formulating the delafloxacin API into its final dosage forms (oral tablets and IV solution).

• Melinta's Network: Melinta Therapeutics likely utilizes a network of CDMOs for its commercial supply.
  • Example CDMO Capabilities: Facilities equipped for high-potency API handling, sterile injectable manufacturing (aseptic filling, lyophilization), and oral solid dosage manufacturing (tablet compression, coating).
• Potential Generic FDP Manufacturers: Generic drug companies will partner with CDMOs to manufacture their abbreviated new drug applications (ANDA) products. The selection criteria will include GMP compliance, regulatory history, cost, and capacity.

Regulatory Landscape and Supply Chain Security

Regulatory compliance is paramount throughout the BAXDELA supply chain.

• FDA and EMA Oversight: Both the FDA and EMA conduct rigorous inspections of manufacturing facilities and review quality data to ensure the safety, efficacy, and quality of pharmaceutical products.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, and quality controls for an API. Generic companies can reference these DMFs in their ANDA filings.
• Supply Chain Traceability: Regulations increasingly mandate robust supply chain traceability to prevent counterfeiting and ensure product integrity. This includes serialization and track-and-trace systems.
• Quality Agreements: Formal quality agreements between the drug product manufacturer and its API suppliers are essential for defining responsibilities, quality standards, and procedures for managing deviations and changes.

Competitive Intelligence and Due Diligence

For businesses evaluating investment or partnership opportunities related to BAXDELA, several areas of due diligence are critical:

1. Patent Landscape Analysis: A thorough review of all granted patents, pending applications, and any post-grant challenges or reexamination proceedings related to delafloxacin. This includes assessing the strength and enforceability of remaining exclusivity.
2. API Sourcing: Identifying and qualifying potential API manufacturers. This involves assessing their technical capabilities, regulatory compliance history (FDA/EMA inspections, GMP certifications), capacity, and cost structures. Due diligence may include site audits.
3. CDMO Capabilities: Evaluating CDMOs for finished drug product manufacturing. Key considerations include expertise in the relevant dosage forms (oral solids, injectables), regulatory track record, capacity, technology, and supply chain security.
4. Regulatory Status: Understanding the current regulatory status of delafloxacin in target markets, including any existing ANDAs filed by potential generic competitors or any active investigations by regulatory bodies.
5. Supply Chain Risk Assessment: Evaluating potential risks in the supply chain, such as geopolitical instability in manufacturing regions, single-source dependencies for critical raw materials or intermediates, and the impact of potential future regulatory changes.

Key Takeaways

• BAXDELA's core compound patent is approaching expiration, creating opportunities for generic entry.
• Additional formulation and method of use patents provide a secondary layer of market exclusivity for the innovator.
• The delafloxacin API synthesis is complex, requiring specialized chemical manufacturers.
• Potential API suppliers are likely concentrated in regions with established pharmaceutical chemical industries, such as India and China, alongside specialty chemical providers.
• Finished drug product manufacturing relies on CDMOs with expertise in sterile injectables and oral solid dosage forms.
• Rigorous regulatory compliance (GMP) and robust supply chain security are essential for all participants.
• Thorough patent analysis, API and FDP supplier due diligence, and supply chain risk assessment are critical for strategic decision-making.

Frequently Asked Questions

1. When is the primary patent for delafloxacin expected to expire in the United States? The U.S. patent covering the delafloxacin compound (U.S. Patent No. 7,375,089) was scheduled to expire in March 2025, though patent term extensions may have adjusted this effective date.

2. Which countries are primary manufacturing hubs for generic pharmaceutical APIs and intermediates that could be relevant to delafloxacin production? India and China are significant global hubs for API and intermediate manufacturing, known for their extensive chemical synthesis capabilities and cost-effectiveness.

3. What specific regulatory filings are critical for generic delafloxacin manufacturers to reference when seeking approval? Generic manufacturers typically file Abbreviated New Drug Applications (ANDAs) in the U.S. and rely on Drug Master Files (DMFs) submitted by their API suppliers.

4. Beyond API suppliers, what other types of specialized manufacturing partners are crucial for bringing a finished drug product like BAXDELA to market? Contract Development and Manufacturing Organizations (CDMOs) are crucial for formulation development, manufacturing of the finished dosage forms (tablets, injectables), packaging, and sterile processing.

5. What are the primary challenges associated with securing a reliable supply chain for a complex antibiotic like delafloxacin? Challenges include ensuring consistent API quality from multiple potential suppliers, managing the complexity of multi-step chemical synthesis, maintaining rigorous GMP compliance across all manufacturing sites, and navigating evolving global regulatory requirements for supply chain traceability.

Citations

[1] United States Patent and Trademark Office. (2008). U.S. Patent 7,375,089: Fluoroquinolone Compounds. [2] United States Patent and Trademark Office. (2016). U.S. Patent 9,370,543: Delafloxacin Mesylate Salt and Use Thereof. [3] United States Patent and Trademark Office. (2019). U.S. Patent 10,183,943: Method for Treating Bacterial Infections with Delafloxacin.